Last $30.83 USD
Change Today +0.52 / 1.72%
Volume 1.2M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

C. Frank Bennett BSc, Ph.D.

Senior Vice President of Antisense Research, Isis Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 3 different industries.

57$958,865
As of Fiscal Year 2013

Background*

Dr. C. Frank Bennett, BSc, Ph.D. serves as Senior Vice President of Antisense Research at Isis Pharmaceuticals, Inc. Dr. Bennett served as Senior Vice President of Antisense Research of Isis Pharmaceuticals, Inc. since January 2006. Dr. Bennett is one of the founding members of Isis. He is involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory and cancer targets, oligonucleotide ...

Read Full Background

Corporate Headquarters*

2855 Gazelle Court
Carlsbad, California 92010

United States

Phone: 760-931-9200
Fax: --

Board Members Memberships*

Former Director
Former Director and Member of the Scientific Advisory Board

Education*

PhD
Baylor College of Medicine
BS
University of New Mexico

Other Affiliations*

Annual Compensation*

Salary$397,077
Bonus$234,524
Total Annual Compensation$631,601

Stock Options*

Restricted Stock Awards$83,145
All Other Compensation$20,038
Exercised Options89,945
Exercised Options Value$1,367,979
Exercisable Options108,189
Exercisable Options Value$2,986,721
Unexercisable Options54,988
Unexercisable Options Value$1,514,332
Total Value of Options$5,869,032
Total Number of Options253,122

Total Compensation*

Total Annual Cash Compensation$651,639
Total Short Term Compensation$631,601
Other Long Term Compensation$103,183
Total Calculated Compensation$958,865
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $30.83 USD +0.52

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
4.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$249.8K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2012.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.